「cc」の検索結果
30件：11～15件目を表示
-
n of Phase III Clinical Trials in Japan for “SJP-0008” for the treatment of Central Retinal Artery Occlusion Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; ...
https://www.senju.co.jp/system/files/content_news/2024-05/ENG_20240509.pdf -
torial disease characterized by an unstable tear film causing discomfort and/or visual impairment, accompanied by ocular surface disorder” *. Recently, the number of DED patients has been increasing d...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117_0.pdf -
n of Phase III Clinical Trials in Japan for “SJP-0008” for the treatment of Central Retinal Artery Occlusion Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; ...
https://www.senju.co.jp/system/files/content_news/2024-05/ENG_20240509_0.pdf -
torial disease characterized by an unstable tear film causing discomfort and/or visual impairment, accompanied by ocular surface disorder” *. Recently, the number of DED patients has been increasing d...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117.pdf -
ho.jp/light_up/ ― 2024 年 当社ライトアップの様子 ― [本件についてのお問い合わせ先] 千寿製薬株式会社 広報室 〒541-0048 大阪市中央区瓦町三丁目１番９号 Mail：cc@senju.co.jp URL：https://www.senju.co.jp 以上
https://www.senju.co.jp/system/files/content_news/2025-02/JPN_20250303.pdf